Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rational drug design paradigms: the odyssey for designing better drugs.
Kellici T, Ntountaniotis D, Vrontaki E, Liapakis G, Moutevelis-Minakakis P, Kokotos G, Hadjikakou S, Tzakos AG, Afantitis A, Melagraki G, Bryant S, Langer T, Di Marzo V, Mavromoustakos T. Kellici T, et al. Comb Chem High Throughput Screen. 2015;18(3):238-56. doi: 10.2174/1386207318666150305125638. Comb Chem High Throughput Screen. 2015. PMID: 25747445 Review.
Leveraging NMR and X-ray Data of the Free Ligands to Build Better Drugs Targeting Angiotensin II Type 1 G-Protein Coupled Receptor.
Kellici TF, Ntountaniotis D, Kritsi E, Zervou M, Zoumpoulakis P, Potamitis C, Durdagi S, Salmas RE, Ergun G, Gokdemir E, Halabalaki M, Gerothanassis IP, Liapakis G, Tzakos A, Mavromoustakos T. Kellici TF, et al. Curr Med Chem. 2016;23(1):36-59. doi: 10.2174/0929867323666151117122116. Curr Med Chem. 2016. PMID: 26572611 Review.
Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.
Ntountaniotis D, Andreadelis I, Kellici TF, Karageorgos V, Leonis G, Christodoulou E, Kiriakidi S, Becker-Baldus J, Stylos EK, Chatziathanasiadou MV, Chatzigiannis CM, Damalas DE, Aksoydan B, Javornik U, Valsami G, Glaubitz C, Durdagi S, Thomaidis NS, Kolocouris A, Plavec J, Tzakos AG, Liapakis G, Mavromoustakos T. Ntountaniotis D, et al. Among authors: kellici tf. Mol Pharm. 2019 Mar 4;16(3):1255-1271. doi: 10.1021/acs.molpharmaceut.8b01212. Epub 2019 Feb 13. Mol Pharm. 2019. PMID: 30681344
Investigation of the interactions of silibinin with 2-hydroxypropyl-β-cyclodextrin through biophysical techniques and computational methods.
Kellici TF, Ntountaniotis D, Leonis G, Chatziathanasiadou M, Chatzikonstantinou AV, Becker-Baldus J, Glaubitz C, Tzakos AG, Viras K, Chatzigeorgiou P, Tzimas S, Kefala E, Valsami G, Archontaki H, Papadopoulos MG, Mavromoustakos T. Kellici TF, et al. Mol Pharm. 2015 Mar 2;12(3):954-65. doi: 10.1021/mp5008053. Epub 2015 Feb 19. Mol Pharm. 2015. PMID: 25665128
Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation.
Stylos E, Chatziathanasiadou MV, Tsiailanis A, Kellici TF, Tsoumani M, Kostagianni AD, Deligianni M, Tselepis AD, Tzakos AG. Stylos E, et al. Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2609-2618. doi: 10.1016/j.bbagen.2017.08.018. Epub 2017 Aug 24. Biochim Biophys Acta Gen Subj. 2017. PMID: 28844979
30 results